ADT-3 / Takeda - LARVOL DELTA

Second Abingworth gamma delta T cell company, Adaptate Biotherapeutics, to be acquired by Takeda (PRNewswire) - "Abingworth...announces its portfolio company Adaptate Biotherapeutics is to be acquired by Takeda Pharmaceutical Company Limited for a pre-negotiated upfront payment....Through the acquisition, Takeda will acquire Adaptate's antibody-based γδ T-cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate's γδ T-cell engagers are engineered to specifically activate γδ T cell-mediated immune responses at tumour sites while sparing damage to healthy cells."

M&A • Oncology